IBD and Menopause - a podcast by Amber J Tresca

from 2023-10-17T04:00

:: ::

Menopause is a topic that's not well understood in general and there's even less information when it comes to menopause and inflammatory bowel disease (IBD, Crohn’s disease and ulcerative colitis). October is World menopause Awareness Month. World Menopause Day is on October 18 every year. The purpose of the day is to raise awareness of menopause and the support options available for improving health and well being. Learn more about how IBD may affect perimenopause and menopause, as well as the reverse.
 
Concepts discussed on this episode:
Find Amber J Tresca at:
Find Mac Cooney (mix, sound design, and theme music) at:
Episode transcript and more information at: https://bit.ly/AIBD139
 

Sources:

1. Rolston VS, Boroujerdi L, Long MD, et al. The influence of hormonal fluctuation on inflammatory bowel disease symptom severity—a cross-sectional cohort study. Inflamm Bowel Dis. 2018;24:387–393. doi:10.1093/ibd/izx004

2. Lichtarowicz A, Norman C, Calcraft B, Morris JS, Rhodes J, Mayberry J. A study of the menopause, smoking, and contraception in women with Crohn's disease. Quarterly Journal of Medicine. 1989;72:623–631.

3. Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1193–1196. doi:10.1111/j.1572-0241.2007.01700.x

4. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028

5. Lungaro L, Costanzini A, Manza F, et al. Impact of Female Gender in Inflammatory Bowel Diseases: A Narrative Review. J Pers Med. 2023;13(2):165. Published 2023 Jan 17. doi:10.3390/jpm13020165

6. Lewandowski K, Kaniewska M, Więcek M, et al. Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease-Do We Already Know Everything?. Nutrients. 2023;15(5):1151. Published 2023 Feb 24. doi:10.3390/nu15051151

7. Schüle S, Rossel JB, Frey D, et al. Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine (Baltimore). 2017;96(22):e6788. doi:10.1097/MD.0000000000006788

8. Hidalgo DF, Boonpheng B, Phemister J, Hidalgo J, Young M. Inflammatory bowel disease and risk of osteoporotic fractures: A meta-analysis. Cureus. 2019;11:e5810. doi:10.7759/cureus.5810

9. Palomba S, Manguso F, Orio F Jr, et al. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause. 2008;15(4 Pt 1):730-736. doi:10.1097/gme.0b013e318159f190

Additional Sources:

  • Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am. 2011;38:425–440. doi:10.1016/j.ogc.2011.05.002
  • Sheth T, Pitchumoni CS, Das KM. Musculoskeletal manifestations in inflammatory bowel disease: a revisit in search of immunopathophysiological mechanisms. J Clin Gastroenterol. 2014;48:308–317. doi:10.1097/MCG.0000000000000067
  • Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239–254. doi:10.1093/ecco-jcc/jjv213

Further episodes of About IBD

Further podcasts by Amber J Tresca

Website of Amber J Tresca